T2 Biosystems Announces Preliminary Third Quarter 2024 Financial …

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance …

CouponFollow Extension

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial

1 week from now

1 day ago · Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew …

globenewswire.com

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024

1 week from now

Oct 7, 2024 · T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period October 07, 2024 09:00 …

globenewswire.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter 2024 Financial ResultsTotal revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew …

nasdaq.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Achieved 34% quarterly revenue growth compared to the prior year period. LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. …

biospace.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Achieved 34% quarterly revenue growth compared to the prior year periodLEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. …

yahoo.com

34%
OFF

T2 Biosystems Announces Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter 2024 Financial Results Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew …

businessinsider.com

$2417304
OFF

The Healthcare Foundation Of NJ Announces $2,417,304 In Third …

1 week from now

Sep 18, 2024 · The Healthcare Foundation of NJ (HFNJ) is pleased to announce that it has awarded $2,417,304 to eighteen nonprofit organizations in its third quarterly grant cycle of …

hfnj.org

2%
OFF

New Jersey MarketBeats | US | Cushman & Wakefield

1 week from now

Oct 8, 2024 · Financial Services; Legal; View All Industries; People; Insights. ... Northern New Jersey's office vacancy rate climbed to 23.2% by the end of the third quarter of 2024, up 160 …

cushmanwakefield.com

49%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial …

1 week from now

Oct 7, 2024 · The Company now expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million, representing growth of 49% to 109% compared to the fourth quarter of …

tmcnet.com

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial ...

1 week from now

Oct 7, 2024 · Achieved 35% increase in total revenue compared to prior year period. LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: …

biospace.com

35%
OFF

T2 Biosystems Announces Preliminary Third Quarter 2024 Financial

1 week from now

Achieved 35% increase in total revenue compared to prior year period LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. ( TTOO), a lead 🚀 Enjoy a 7-Day Free …

gurufocus.com

FAQs about T2 Biosystems Announces Preliminary Third Quarter 2024 Financial … Coupon?

What did T2 Biosystems do in Q3 2024?

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the third quarter 2024. Recent Financial and Operational Highlights (unaudited) ...

How much money did t2biothreat raise in Q4 2024?

The Company raised $4.3 million in net proceeds with our ATM during the quarter and $3.2 million since September 30, 2024. The Company expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million. This target does not include potential sales of the T2Biothreat™ Panel or the T2Lyme™ Panel. ...

Who is T2 Biosystems?

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. ...

What is t2biothreat's fourth quarter 2024 revenue guidance?

The Company now expects fourth quarter 2024 total sepsis product revenue of $2.5 million to $3.5 million, representing growth of 49% to 109% compared to the fourth quarter of 2023. The Company’s 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat™ Panel or the T2Lyme™ Panel. ...

How did sepsis ® perform in the third quarter of 2024?

Total revenue for the third quarter of 2024 was $2.0 million, an increase of 34% compared to the prior year period. Sepsis test revenue grew 34% compared to the prior year period, led by T2Bacteria ®. ...

How did the third quarter of 2024 compare to the prior year?

Cost of product revenue for the third quarter of 2024 was $4.1 million, a 4% increase compared to the prior year period driven by increased international instrument and sepsis test sales. Research and development expenses were $2.7 million, which is comparable to the prior year period. ...